Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Employment agrmnt

Orchard Therapeutics plc (ORTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 DEFA14C Form DEFA14C - Additional information statement materials, definitive:
10/05/2023 DEFA14C Form DEFA14C - Additional information statement materials, definitive:
10/05/2023 DEFA14C Form DEFA14C - Additional information statement materials, definitive:
10/05/2023 DEFA14C Form DEFA14C - Additional information statement materials, definitive:
10/05/2023 DEFA14C Form DEFA14C - Additional information statement materials, definitive:
10/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/05/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Form of Irrevocable Undertaking",
"TRANSACTION AGREEMENT by and between KYOWA KIRIN CO., LTD. and ORCHARD THERAPEUTICS PLC Dated as of October 5, 2023",
"Form of Irrevocable Undertaking",
"Kyowa Kirin to Acquire Orchard Therapeutics"
08/22/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/21/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA Reported $6.6M in Q2’23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT",
"FTD BONE INTESTINE BRAIN LIVER MPS-IH HSC"
06/16/2023 4 Altschuler Steven (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 Curnutte John T (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 Dunoyer Marc (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 GERAGHTY JAMES A (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 Beck Joanne T. (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 Secor Alicia (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
06/16/2023 4 Rowland Charles A Jr (Director) has filed a Form 4 on Orchard Therapeutics plc
Txns: Granted 105,000 options to buy @ $0.495, valued at $52k
05/23/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TIME AGENDA TOPIC SPEAKERS 8:00",
"Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatment for autoimmune disorders Company to host conference call and webcast Tuesday, May 23 at 8:00 a.m. EDT BOSTON and LONDON, May 18, 2023, -- Orchard Therapeutics , a global gene therapy leader, today presented new data from the company’s hematopoietic stem cell gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Socie...",
"Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study in MPS-IIIA patients show additional favorable neurocognitive outcomes compared to disease natural history with median follow-up of 2.5 years First preclinical data for OTL-204 highlight ability of HSC gene therapy to restore microglial function, modulate neuroinflammation, and normalize predictive biomarkers in the progranulin form of frontotemporal dementia Company to host co..."
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA OTL-200 Biologics License Application submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data in MPS-I and MPS-IIIA and pre-clinical data in genetic subsets of frontotemporal dementia and Crohn’s to be presented this week at ASGCT Closed initial $34M of potential $188M in proceeds as part of strategic financing and ended Q1 2023 with $146M of cash and investments and runway into 2025"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/27/2023 8-K Quarterly results
03/23/2023 D Form D - Notice of Exempt Offering of Securities:
03/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/20/2023 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in ORCHARD THERAPEUTICS PLC
03/14/2023 4 THOMAS FRANK E (See Remarks) has filed a Form 4 on Orchard Therapeutics plc
Txns: Exercised 20,000 options to buy @ $0.4591, valued at $9.2k
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "FORM 8-K",
"Form of Warrant",
"Securities Purchase Agreement dated March 6, 2023, by and among Orchard Therapeutics plc and the Purchasers named therein",
"Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy